α-Substituted proline derivatives are widely used in medicinal chemistry, particularly in peptide-based drug discovery and peptidomimetic design.
Ceralasertib is an oral ATR (ataxia-telangiectasia and Rad3-related) kinase inhibitor developed by AstraZeneca and currently being evaluated in late-stage clinical trials for advanced solid tumors (for example, post-immunotherapy or platinum-treated NSCLC and ovarian cancer).
Imlunestrant (brand name Inluriyo®) is an oral small-molecule selective estrogen receptor degrader (SERD) developed by Eli Lilly.
Nitrogen-containing heterocycles play a pivotal role in modern medicinal chemistry, particularly pyrazine structures, which are widely applied in oncology research and other therapeutic areas.
Remibrutinib (trade name Rhapsido®) was approved by the U.S. FDA on September 30, 2025, for the treatment of adults with chronic spontaneous urticaria (CSU) who have an inadequate response to H1 antihistamines.
Seralutinib is a next-generation inhaled small-molecule tyrosine kinase inhibitor developed by Gossamer Bio and is currently in Phase 3 clinical trials for the treatment of pulmonary arterial hypertension (PAH).